

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Gerald M. Murphy, Jr.* #36,623
Gerald M. Murphy, Jr., #28,977

GMM/cqc
2921-0130P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

VERSION WITH MARKINGS SHOWING CHANGES MADE

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

5. (Amended) A protein according to claim 1 or a nucleic acid according to [any one of claims 2-4]claim 2 for use as a medicament.

6. (Amended) Use of a protein according to claim 1 or a nucleic acid according to [any one of claims 2-4]claim 2 in the manufacture of a medicament for the treatment of a condition involving tumors, such as BSS.

7. (Amended) A method of in vitro or in vivo diagnosis, wherein a protein according to claim 1 or a nucleic acid according to [any one of claims 2-4]claim 2 is used.

11. (Amended) A vector comprising a nucleic acid according to [any one of claims 2-4]claim 2.

15. (Amended) A kit for the detection of human PTCH2 gene or polypeptide comprising in a container a molecule selected from the group consisting of a nucleic acid according to [any one of claims 2-4]claim 2, a protein according to claim 1 or an antibody according to claim 13.

16. (Amended) Use of a nucleic acid according to [any one of claims 2-4]claim 2 in gene therapy.

09807007.07901
T06040" 40020860